Although it has shown high efficacy in many tumor types, interleukin-12 (IL-12) treatment provokes severe systemic toxicity. Here, the authors discover that use of an IL-12Fc fusion cytokine with abolished binding to the neonatal Fc receptor presents efficacy in local glioblastoma therapy while preventing toxicity.
- Michal Beffinger
- Linda Schellhammer
- Johannes vom Berg
